Health-related quality of life in patients with KRAS(G12C)-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial.
- DOI
- 10.1016/s1470-2045(25)00352-3
- Published
- 2025 Sep
- Container
- The Lancet. Oncology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s1470-2045-25-00352-3,
title = {Health-related quality of life in patients with KRAS(G12C)-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial.},
author = {Modest DP and Fakih M and Salvatore L and Esaki T and Lopez-Bravo DP and Taieb J and Karamouzis M and Ruiz-Garcia E and Kim TW and Kuboki Y and Meriggi F and Cunningham D and Yeh KH and Cremolini C and Tran Q and Chan E and Chao J and Majer IM and Pietrantonio F},
year = {2025},
journal = {The Lancet. Oncology},
doi = {10.1016/s1470-2045(25)00352-3},
url = {https://doi.org/10.1016/s1470-2045(25)00352-3}
}RIS
TY - JOUR TI - Health-related quality of life in patients with KRAS(G12C)-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial. AU - Modest DP AU - Fakih M AU - Salvatore L AU - Esaki T AU - Lopez-Bravo DP AU - Taieb J AU - Karamouzis M AU - Ruiz-Garcia E AU - Kim TW AU - Kuboki Y AU - Meriggi F AU - Cunningham D AU - Yeh KH AU - Cremolini C AU - Tran Q AU - Chan E AU - Chao J AU - Majer IM AU - Pietrantonio F PY - 2025 JO - The Lancet. Oncology DO - 10.1016/s1470-2045(25)00352-3 UR - https://doi.org/10.1016/s1470-2045(25)00352-3 ER -
APA
DP, M., M, F., L, S., T, E., DP, L., J, T., M, K., E, R., TW, K., Y, K., F, M., D, C., KH, Y., C, C., Q, T., E, C., J, C., IM, M., & F, P. (2025). Health-related quality of life in patients with KRAS(G12C)-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(25)00352-3
Source records
- pubmed · retrieved 2026-09-26T21:50:33.294Z